Werewolf Therapeutics (NASDAQ:HOWL) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a report released on Monday, Benzinga reports. They currently have a $15.00 price objective on the stock.

Separately, JMP Securities began coverage on shares of Werewolf Therapeutics in a report on Wednesday, April 3rd. They set a mkt outperform rating and a $12.00 price target on the stock.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock opened at $5.98 on Monday. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.29. The stock has a 50-day moving average price of $6.21 and a two-hundred day moving average price of $4.67. Werewolf Therapeutics has a 12 month low of $1.57 and a 12 month high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.10. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. The business had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.75 million. On average, equities research analysts expect that Werewolf Therapeutics will post -1.38 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Financial Perspectives Inc lifted its position in shares of Werewolf Therapeutics by 80.0% in the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after purchasing an additional 3,000 shares during the period. Certuity LLC bought a new position in Werewolf Therapeutics during the fourth quarter worth $39,000. Lighthouse Investment Partners LLC acquired a new position in Werewolf Therapeutics in the fourth quarter valued at $87,000. Denali Advisors LLC bought a new stake in Werewolf Therapeutics during the first quarter valued at $172,000. Finally, PFM Health Sciences LP boosted its position in Werewolf Therapeutics by 35.6% during the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after acquiring an additional 909,895 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.